Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26558088 | 0.91 | TOP2A (0.35) | CYP3A4SMYD2HTTSMN1; SMN2TOP2A | |
| SCHEMBL26558108 | 0.88 | SMYD2 (0.34) | CYP3A4SMYD2HTT | |
| SCHEMBL26558166 | 0.86 | TSHR (0.37) | CYP3A4SMYD2SMN1; SMN2 | |
| SCHEMBL26558122 | 0.83 | TOP2A (0.33) | CYP3A4TOP2A | |
| SCHEMBL26558143 | 0.83 | SMYD2 (0.33) | CYP3A4SMYD2HTTSMN1; SMN2ABL1 | |
| SCHEMBL723798 | 0.82 | SMYD2 (0.40) | CYP3A4SMYD2HTTSMN1; SMN2TOP2A | |
| SCHEMBL26558123 | 0.81 | — | — | |
| SCHEMBL26558041 | 0.80 | SMYD2 (0.34) | CYP3A4SMYD2HTT | |
| SCHEMBL10268793 | 0.78 | CYP3A4 (0.34) | CYP3A4SMYD2TOP2A | |
| SCHEMBL26558127 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | CYP3A4 1370/4885SMYD2 2335/4885HTT 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.